Abstract 729P
Background
Nodal metastases (N+) are one of the most powerful predictors of disease recurrence after surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs). However, the prognostic role of nodal metastases < 5 mm, defined as micrometastases, has been poorly investigated so far. The aim of this study was to compare clinico-pathological features and survival outcomes between patients with NF-PanNETs without nodal involvement (N0), with nodal micrometastases (microN+) and with nodal macrometastases (macroN+).
Methods
Consecutive patients who underwent a formal pancreatic resection for NF-PanNETs at San Raffaele Hospital (Milan, Italy) between 2018 and 2021 and were enrolled in the DETECTYON trial were considered (NCT03918759). Nodal metastases were further classified as microN+ when their maximum diameter was < 5 mm, or as macroN+ when their maximum diameter was ≥ 5 mm.
Results
Overall, 100 patients were included. Of these, 58 had N0 PanNETs, 15 had microN+ and 27 had macroN+. Patients with macroN+ had significantly larger tumors [median 35 mm (IQR 28-47)] as compared to patients with microN+ [25 mm (IQR 24-35), p=0.040] and N0 neoplasms (26 mm (IQR 18-34), p=0.003]. The rate of G2-G3 neoplasms was comparable between patients with N0 and microN+ PanNETs (45% versus 27%, p=0.203), whereas it was significantly higher among subjects with macroN+ tumors (n=21/27 - 78%). Median Ki67 was 2% in patients with N0 and microN+ neoplasms (p=0.429), whereas it increased to 6% in patients with macroN+ (p=0.006). After a median follow-up of 37 months, 16 patients (16%) experienced disease relapse. Patients with N0 PanNETs had a 4-year DFS rate of 97% as compared with 88% and 43% in patients with microN+ (p=0.152) and macroN+ (p<0.001), respectively. At multivariable analysis, distant metastases (HR 5.826, p=0.026) and macroN+ (HR 6.281, p=0.034) were identified as independent determinants of disease relapse.
Conclusions
NF-PanNETs with microN+ seem to be associated with a risk of recurrence similar to N0 neoplasms. MicroN+ may be regarded as a clinicopathological entity separate from macroN+, with a possible impact on postoperative surveillance protocols.
Clinical trial identification
These are the long-term outcomes of a prospective observational study: NCT03918759.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11